Jacubo First-Quarter Prescription Sales Reach 21.2 Billion Won, Up 217% Year-on-Year

Jacubo (ingredient name: Zastaprazan), a domestically developed potassium-competitive acid blocker (P-CAB) for the treatment of gastroesophageal reflux disease, has continued its rapid growth since its launch.

Image of Jacubojeong, a domestic gastroesophageal reflux disease treatment product. Jeil Pharmaceutical

원본보기 아이콘

Jeil Pharmaceutical announced on April 16 that Jacubo’s outpatient prescription sales in the first quarter of this year reached 21.2 billion won, up 217.6% from 6.68 billion won in the same period last year. This represents an increase of approximately 3.17 times year-on-year.

Jacubo received approval from the Ministry of Food and Drug Safety as a treatment for erosive gastroesophageal reflux disease in April 2024 and was launched in Korea in October of the same year. Since then, the product line has expanded by adding indications for gastric ulcer and an orally disintegrating tablet formulation. In just about a year and a half since its launch, its cumulative prescription sales have reached 72.8 billion won.

According to the pharmaceutical market research agency UBIST, Jacubo’s outpatient prescription sales in March of this year amounted to 8 billion won, setting a new monthly record. Jacubo also entered the top ranks in the domestic pharmaceutical market based on first-quarter prescription sales.

Jacubo is known as a potassium-competitive P-CAB that offers faster onset of action compared to conventional proton pump inhibitors (PPI). Jeil Pharmaceutical is working to expand the market through joint sales efforts with DongA ST.

Currently, phase 3 clinical trials are underway for the prevention of NSAID-induced ulcers and for non-erosive gastroesophageal reflux disease. An additional phase 3 clinical trial is also being conducted for maintenance therapy in erosive gastroesophageal reflux disease.

A representative from Jeil Pharmaceutical stated, "We plan to broaden the range of prescriptions by expanding the indications."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.